The year 2026 marks a significant turning point in the pharmaceutical industry with the patent expiration of seven blockbuster drugs. This presents unique investment opportunities in generic and biosimilar manufacturers, as well as for innovative companies poised to fill market gaps. Understand the financial implications and strategic moves for investors.

This investor's guide unveils the top three gene editing technologies—CRISPR, Base Editing, and Prime Editing—poised for explosive growth by mid-2026, offering crucial insights for strategic biotech investment decisions.

JPM Healthcare 2025 offered crucial insights for biotech startups, highlighting evolving funding models, strategic partnership opportunities, and the imperative of embracing AI and personalized medicine to thrive in a competitive market.